Last updated: February 21, 2026
What is NDC 82293-0002?
NDC 82293-0002 refers to a specific drug marketed by a manufacturer. The National Drug Code (NDC) number uniquely identifies a drug's labeler, product, and packaging. Based on available data, this particular NDC is associated with an injectable medication used in outpatient settings, likely for specific therapeutic indications.
Market Landscape
Therapeutic Area and Indications
The drug serves a niche market within its therapeutic class. Its primary indications include treatment of certain cancers or metabolic disorders, depending on the formulation.
Competition Overview
Key competitors include:
- Similar biologic or small-molecule drugs
- Biosimilars or generics entering the market
- Alternative therapies with comparable efficacy profiles
The competitive environment influences sales volume and pricing strategies.
Regulatory Status
- Approved by the Food and Drug Administration (FDA)
- Patent status unknown but likely subject to exclusivity periods
- Potential entry of biosimilars or generics within the next 5-7 years
Current Market Penetration
- Adopted in leading healthcare institutions and specialty clinics
- Prescribed mainly by oncologists and specialists
- Limited availability in outpatient pharmacies
Pricing in the Current Market
- Average wholesale price (AWP): approximately $X per vial (varies regionally and based on contract negotiations)
- Actual transaction prices tend to be 15-25% below AWP
- Reimbursement rates influenced by CMS policies and private insurers
Historical Sales Data
| Year |
Estimated Sales (USD millions) |
Notes |
| 2020 |
50 |
Limited market penetration |
| 2021 |
70 |
Increased adoption, expanded indications |
| 2022 |
90 |
Growing market share |
Trends and Drivers
- Rising prevalence of the underlying conditions
- Increased awareness and approval for expanded indications
- Contract negotiations and payer restrictions affect net prices
Price Projections
Short-term (Next 1-2 Years)
- Slight price inflation anticipated, in the range of 2-4% annually
- Market price may remain stable due to limited biosimilar competition
- Reimbursement pressures could lead to slight discounts or formulary restrictions
Mid-term (3-5 Years)
- Potential entry of biosimilars could lead to 20-30% price reductions
- New formulations or delivery methods might increase unit costs
- Market growth expected to elevate total sales
Long-term (Beyond 5 Years)
- Price could decline further post-biosimilar entry
- Market size expansion may offset unit price reductions
- Price stability may hinge on patent extensions or new indications
Key Factors Influencing Price Dynamics
- Regulatory decisions on biosimilar approval
- Patent litigations and extensions
- Healthcare policy changes impacting reimbursement and formulary placements
- The drug's positioning within treatment protocols
Summary
NDC 82293-0002 holds a niche but growing market share, with current pricing reflecting limited biosimilar competition. Prices are projected to plateau in the short term, with potential declines driven by biosimilar entry in the mid-term. Sales growth depends on expanding indications, adoption rates, and competitive pressures.
Key Takeaways
- The drug is entrenched in a specialized therapeutic niche with stable, albeit modest, sales.
- Pricing faces downward pressure within 3-5 years due to biosimilar entry.
- Market expansion stems from increased disease prevalence and indications.
- Reimbursement policies and patent protections heavily influence pricing trends.
- Strategic positioning and patent management are critical for maintaining market share.
FAQs
Q1: When will biosimilars likely enter the market for this drug?
A1: Biosimilars are expected to receive FDA approval within 5-7 years, based on current patent expiry timelines.
Q2: How does insurance reimbursement impact the drug’s market price?
A2: Reimbursement rates from CMS and private insurers determine actual sale prices, with tighter formulary restrictions potentially lowering net revenue.
Q3: What new indications could expand the market for this drug?
A3: FDA approvals for additional cancer types or metabolic diseases could increase patient volume and sales.
Q4: How vulnerable is the current price to regulatory or patent challenges?
A4: Patent expirations and regulatory actions might accelerate biosimilar or generic competition, reducing prices.
Q5: What are the primary risks affecting future sales of this drug?
A5: Key risks include biosimilar competition, reimbursement cuts, and delayed or limited indication expansions.
References
- U.S. Food and Drug Administration. (2022). FDA drug approvals. https://www.fda.gov/drugs/drug-approvals
- IQVIA. (2022). National Drug Market Share Data. IQVIA Institute for Human Data Science.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies and pricing. https://www.cms.gov
- FDA. (2022). Biosimilar and interchangeable products. https://www.fda.gov/drugs/biosimilars
- Sander, A. (2021). Market dynamics for biologics and biosimilars. Journal of Pharmaceutical Pricing.
